Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
16995
Approved small_molecule completed
Quick answer
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) for Neovascular Macular Degeneration is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Neovascular Macular Degeneration
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed